RESUMO
Four series of new acridine derivatives of anticipated antitumor activity have been designed and synthesized. The first series belongs to 4-substituted phenylhydrazinocarbonylmethyl 9-oxo-9,10-dihydroacridine-4-carboxylate 10a-h. The second series consists of phenylhydrazinocarbonylmethyl 9-[4-substituted phenyl]aminoacridine-4-carboxylate 12a-k, while the third series comprises 4-substituted phenylcarbonylmethyl 9-[4-substituted phenyl]aminoacridine-4-carboxylate 15a-k. The fourth one belongs to phenylcarbamoylmethyl 9-[4-substituted phenyl]aminoacridine-4- carboxylate 17a-j. The chemical structure of synthesized compounds was elucidated by spectral data and elemental analysis. Seventeen selected compounds [10a, 10g, 10h, 12at 12d, 12g, 12h, 12k, 15a, 15c, 15g, 15h, 15k, 17a, 17f, 17g and 17j] were tested against breast cancer cell line [MCF7] and eight compounds [12g, 12h, 12k, 15g, 15h, 17f, 17g, 17j] were found to exhibit significant antitumor activity